Hallmark 8 of 12

Cellular senescence

A senescent cell has decided never to divide again but remains metabolically active. In popular accounts they are called zombie cells, which stresses what is disruptive and omits what is useful. Senescence is simultaneously a protective mechanism against cancer and a prerequisite for wound healing. It becomes problematic only when such cells accumulate.

Scientific term: Cellular senescence
Group: Antagonistic responses
Hallmarks of Aging: Described in 2013

The hallmarks of aging are a research framework, not a diagnostic tool. They describe processes that occur during ageing, but they do not prove causation and are not a basis for medical decisions.

What lies behind it

Senescence is a stress response. Triggers include critically short telomeres, irreparable DNA damage, activation of oncogenes or sustained metabolic stress. The cell then permanently activates cell cycle brakes, chiefly via the proteins p16 and p21, blocking any further division.

What follows is the decisive part. Senescent cells secrete a characteristic mixture of pro-inflammatory messengers, growth factors and tissue-degrading enzymes. This secretion profile is called the senescence-associated secretory phenotype, or SASP. Through the SASP a single cell acts far beyond itself: it attracts immune cells, alters tissue structure and can drive neighbouring cells into senescence as well.

The biological purpose is protective at first. A cell with dangerous mutations is shut down instead of continuing to multiply. The SASP calls in the immune system, which clears the affected cell. In wound healing and in embryonic development, senescence likewise performs orderly functions.

With age the balance tips for two reasons. More senescent cells arise, and the ageing immune system clears them less well. The remaining cells sustain low-grade inflammation through their SASP, which links this hallmark closely to chronic inflammation.

How robust is the evidence

Moderate evidence

The mechanism is well documented; human data are largely observational.

The animal models are strikingly clear. In genetically modified mice allowing targeted removal of p16-positive cells, clearing them delayed the onset of several age-related changes and, in one study, extended median lifespan. In other work, senolytic compounds improved physical function in old mice, and conversely transplanting senescent cells into young animals caused functional decline.

In humans, research stands considerably further back. Some small early studies exist. In idiopathic pulmonary fibrosis, a combination of dasatinib and quercetin improved individual functional measures in an open-label pilot study without a control group. In diabetic kidney disease, the same combination reduced markers of senescent cells in adipose tissue in a small study. Both studies involved fewer than twenty people and were not designed to demonstrate clinical benefit.

A second human approach is observational. The proportion of p16-positive cells in tissue samples rises with age, and higher values go along with frailty. Such data come from biopsies and are not available in preventive care.

Findings in humans

The proportion of p16-positive cells in tissue samples rises with age and is associated with frailty.
In an open-label pilot study without a control group, dasatinib plus quercetin improved individual functional measures in pulmonary fibrosis.
In diabetic kidney disease, the same combination reduced senescence markers in adipose tissue in a small study.
Both human studies involved fewer than twenty people and were not designed to show clinical benefit.
No validated blood test exists that determines the senescent cell burden in the body.

What of this is measurable at YEARS

Not measurable in preventive care

A person’s senescent cell burden cannot currently be determined. Established detection runs via p16 or senescence-associated beta-galactosidase in tissue samples, meaning a biopsy. For blood there is no validated test. YEARS measures nothing in this context that reflects senescence.

Inflammatory markers as a very distant proxy

High-sensitivity CRP and interleukin-6 capture low-grade inflammation, to which senescent cells can contribute through their SASP. The share is unknown: both values also rise with infection, obesity, autoimmune disease and after intense physical exertion. No inference about senescence can be drawn from them.

Context

If a provider calculates a senescence burden or zombie cell score from your blood, that is not validated. Nor is senolytic treatment justified in healthy people. The available human data come from pilot studies with fewer than twenty participants and were collected in people with existing disease.

Limits of this hallmark

Senescence is not a uniform state. Depending on trigger, cell type and duration, senescent cells differ considerably, including in their SASP. There is no single marker that captures all senescent cells and excludes healthy ones. This heterogeneity is the main reason a blood test is so far lacking, and it also complicates the development of targeted compounds.

The protective character must not be lost. Senescence prevents damaged cells from growing into tumours, and it is needed for orderly wound healing. Broadly removing senescent cells could impair these functions. In animal studies, delayed wound healing and liver problems were also observed depending on the model.

The gap between mouse and human is especially large here. The impressive results come from genetically modified animals in which a defined cell population can be removed at the push of a button. Such an intervention has little in common with a tablet in a human. The available human studies are too small and too short to judge benefit or risk.

Frequently asked questions

What are zombie cells?→

Zombie cells is the popular term for senescent cells. They have permanently stopped dividing but do not die and remain metabolically active. This state is triggered by critically short telomeres, irreparable DNA damage, activated oncogenes or sustained metabolic stress. These cells matter less through their own inactivity than through what they secrete: a mixture of pro-inflammatory messengers and tissue-degrading enzymes known as the SASP. This alters their surroundings and can drive neighbouring cells into senescence too. The term zombie cell stresses what is disruptive and omits that senescence also protects against cancer.

Are senescent cells only harmful?→

No, and this is the key point for a sober assessment. Senescence is a protective mechanism: a cell with dangerous mutations is shut down instead of continuing to divide, which slows tumour formation. It also performs orderly functions in wound healing and embryonic development, and its secretion profile summons the immune system to clear the cell. Senescence becomes a problem only through accumulation. In ageing, more such cells arise and the immune system removes them less well. Blanket removal would therefore not be a pure gain but an intervention in a system with a dual function.

How far along are senolytics in humans?→

At the beginning. Senolytics are compounds intended to drive senescent cells into cell death selectively. In mice the results are impressive: removing these cells delayed several age-related changes and, in one study, extended median lifespan. In humans only small studies exist so far. A combination of dasatinib and quercetin improved individual functional measures in idiopathic pulmonary fibrosis in an open-label pilot study without a control group, and reduced senescence markers in adipose tissue in diabetic kidney disease. Both studies involved fewer than twenty people. For healthy people there is no demonstration of benefit whatsoever, and dasatinib is a cancer drug with a relevant side effect profile.

Can your senescent cell burden be measured?→

Not reliably. Established detection is done in tissue samples, via the proportion of p16-positive cells or senescence-associated beta-galactosidase. That requires a biopsy and is research methodology. No validated blood test exists, for a substantive reason: senescent cells differ greatly among themselves depending on trigger, tissue and duration. There is no single marker that captures all of them and reliably excludes healthy cells. Inflammatory values such as CRP or interleukin-6 stand in distant relation, because senescent cells can contribute to low-grade inflammation, but they are far too non-specific for any conclusion.

Sources

Baker DJ, Childs BG, Durik M, et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature. 2016;530(7589):184–189.
Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018;24(8):1246–1256.
Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554–563.
Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446–456.
Gorgoulis V, Adams PD, Alimonti A, et al. Cellular senescence: defining a path forward. Cell. 2019;179(4):813–827.

Related hallmarks

Hallmark 2 of 12